Objective To observe the clinical effect of modified Shenge Qinglong Wan（ 参蛤青龙丸） in treating bronchial asthma with wheezing due to cold syndrome.Methods With randomly control and the third party evaluation design

the study included 129 patients with acute and chronic bronchial asthma with wheezing due to cold syndrome（ class I-class III）

which were randomly allocated into Chinese medicine group（ 65 cases） and western medicine group（ 64 cases）.In the Chinese medicine group

the patients were treated with modified Shenge Qinglong Wan（ 参蛤青龙丸）

while in the western medicine group

the patients were treated with the salmeterol/flutieasone aerosol（ 50 μg

twice per day）.The course of treatment lasted for 12 weeks.

The asthma control test（ ACT） scores were measured at baseline

and 4 weeks

8 weeks and 12 weeks after treatment

and the lung function was evaluated before and after treatment.The results were analyzed by intention-to-treatment and per-protocol analyses.Confidence interval was used to determine whether ACT scores were non-inferior or not.Results Both ITT and PP analyses showed that

at 4 weeks

8 weeks and 12 weeks after treatment

the 95% CI lower limits of ACT scores were greater than-1.5

suggesting Chinese medicine group being non-inferior to western medicine group.In Chinese medicine group

there was significant difference in 50% forced expiratory flow（ FEF50） between before and after treatment（ P <0.05）.In western medicine group

there were significant difference in forced vital capacity（ FEV1） and FEF50 between before and after treatment（ P < 0.05）.After treatment

there were no significant differences in the lung function measures between the groups（ P > 0.05）.Conclusion In patients with bronchial asthma with wheezing due to cold syndrome（ class Ⅰ—class Ⅲ）

ACT scores in the modified Shenge Qinglong Wan group are non-inferior to those in the salmeterol / flutieasone aerosol group.Both therapies could improve lung function with varying degrees.